HomeAVH • ASX
add
AVITA Medical Inc
Previous close
$2.48
Day range
$2.38 - $2.47
Year range
$2.38 - $6.27
Market cap
303.39M AUD
Avg Volume
444.80K
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 11.10M | 5.25% |
Operating expense | 26.80M | 42.58% |
Net income | -18.66M | -102.36% |
Net profit margin | -168.03 | -92.28% |
Earnings per share | -1.10 | -99.91% |
EBITDA | -17.05M | -74.39% |
Effective tax rate | -0.16% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 68.18M | -7.17% |
Total assets | 97.38M | 5.14% |
Total liabilities | 64.81M | 330.33% |
Total equity | 32.57M | — |
Shares outstanding | 25.79M | — |
Price to book | 1.97 | — |
Return on assets | -41.16% | — |
Return on capital | -51.25% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -18.66M | -102.36% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Avita Medical is a clinical and commercial company developing and marketing a range of respiratory and regenerative products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa and Australia. Wikipedia
Founded
1999
Headquarters
Website
Employees
207
